ELIXIRGEN THERAPEUTICS
Live / Registered — Registered (as of 16 Sept 2025)
What this means for you
Registered since 16 Sept 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97150514
- Registration number
- 7950350
- Mark type
- Design + words
- Filed
- 01 Dec 2021
- Published for opposition
- 09 Jan 2024
- Registered
- 16 Sept 2025
- Attorney of record
- Leonard D. Bowersox
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical drugs for the treatment of infectious diseases, cancer, and aging-related diseases; chemical preparations for medicinal purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases; chemical preparations for pharmaceutical purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases; preparations of organisms for medical purposes, namely, for the treatment of infectious diseases, cancer, and aging-related diseases
- Class 042 — Scientific and technological services: Research and development of vaccines and medicines; testing of pharmaceuticals; research in the field of pharmaceuticals
Owner
- Elixirgen Therapeutics, Inc., Baltimore, MD, US
- Elixirgen Therapeutics, Inc., Baltimore, MD, US
- Elixirgen Therapeutics, Inc., Baltimore, MD, US
Prosecution history
- 16 Sept 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 16 Sept 2025 — REGISTERED-PRINCIPAL REGISTER
- 26 Aug 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 26 Aug 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 25 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 25 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 21 Aug 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 02 Aug 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 02 Aug 2024 — NON-FINAL ACTION E-MAILED
- 02 Aug 2024 — SU - NON-FINAL ACTION - WRITTEN
- 12 Apr 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Mar 2024 — USE AMENDMENT FILED
- 04 Sept 2024 — DIVISIONAL PROCESSING COMPLETE
- 22 Mar 2024 — DIVISIONAL REQUEST RECEIVED
- 04 Sept 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL